- Home
- OABI vs CLDT Comparison
OABI vs CLDT Comparison
Compare OABI & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- CLDT
- Stock Information
- Founded
- OABI 2012
- CLDT 2009
- Country
- OABI United States
- CLDT United States
- Employees
- OABI N/A
- CLDT N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- CLDT Real Estate Investment Trusts
- Sector
- OABI Health Care
- CLDT Real Estate
- Exchange
- OABI Nasdaq
- CLDT Nasdaq
- Market Cap
- OABI 388.5M
- CLDT 450.5M
- IPO Year
- OABI N/A
- CLDT 2010
- Fundamental
- Price
- OABI $3.22
- CLDT $8.80
- Analyst Decision
- OABI Strong Buy
- CLDT Strong Buy
- Analyst Count
- OABI 4
- CLDT 2
- Target Price
- OABI $9.00
- CLDT $12.00
- AVG Volume (30 Days)
- OABI 448.8K
- CLDT 249.4K
- Earning Date
- OABI 11-12-2024
- CLDT 02-25-2025
- Dividend Yield
- OABI N/A
- CLDT 3.18%
- EPS Growth
- OABI N/A
- CLDT N/A
- EPS
- OABI N/A
- CLDT N/A
- Revenue
- OABI $20,409,000.00
- CLDT $313,268,000.00
- Revenue This Year
- OABI N/A
- CLDT N/A
- Revenue Next Year
- OABI $78.61
- CLDT $3.83
- P/E Ratio
- OABI N/A
- CLDT N/A
- Revenue Growth
- OABI N/A
- CLDT 1.77
- 52 Week Low
- OABI $3.16
- CLDT $7.60
- 52 Week High
- OABI $6.55
- CLDT $11.10
- Technical
- Relative Strength Index (RSI)
- OABI 32.70
- CLDT 44.26
- Support Level
- OABI $3.16
- CLDT $8.65
- Resistance Level
- OABI $3.29
- CLDT $8.91
- Average True Range (ATR)
- OABI 0.13
- CLDT 0.21
- MACD
- OABI -0.02
- CLDT 0.00
- Stochastic Oscillator
- OABI 9.09
- CLDT 65.97
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.